the Efficacy and Safety of Ondansetron Oral Soluble Pellicles

Inclusion Criteria:

1. Age ≥18 years, gender is not limited;
2. Histologically or cytologically confirmed diagnosis of malignant solid tumor;
3. Initial highly emetogenic one-day chemotherapy regimen (cisplatin dose 60-75 mg/m2;anthracycline compound adriamycin ≥ 60 mg/m2 or epothilone ≥ 90 mg/m2 ); and
4. Nausea and vomiting prophylaxis with a triple regimen of fosaprepitant + ondansetronorally dissolved membrane + dexamethasone started before chemotherapy;
5. Expected survival ≥ 3 months;
6. Eastern Cooperative Oncology Group (ECOG) physical status score ≤2;
7. Patients were able to read, understand, and complete study questionnaires;
8. Patients understood the study procedures and signed a written informed consent form

Exclusion Criteria:

1. Patients scheduled to receive multiple days of highly emetogenic chemotherapy withinone week;
2. Patients using an antiemetic drug other than the study drug or a drug with anantiemetic active ingredient within 48 h prior to initiation of randomization and/orwithin one week of enrollment;
3. Symptoms such as vomiting prior to randomization;
4. Patients on opioid therapy (except stable dose administration);
5. Patients treated with a chemotherapy regimen containing generic paclitaxel (usingcastor oil as a solvent);
6. Patients who have received, or are expected to receive, radiotherapy to the abdomen (including the diaphragmatic plane and below) or pelvis within 1 week beforerandomization or one week after enrollment;
7. Patients with active infection (e.g., pneumonia) or any uncontrolled disease (e.g.,diabetic ketoacidosis, gastrointestinal obstruction) other than malignancy;
8. The patient has participated in another clinical trial within the past 4 weeks;
9. Any condition that, in the judgment of the investigator, is unstable or may jeopardizethe safety of the subject and his or her compliance with the study;
10. Pregnant or lactating females;
11. Presence of allergic conditions or prior serious adverse reactions to the study drugand excipients;
12. Suffering from psychological, familial, social, or geographic conditions that mayprevent compliance with the study protocol and follow-up schedule;